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I. Lyt-1  Cells Mediate  Skin Graft  Rejection* 
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It is commonly accepted that the in vitro lysis of allogeneic target cells by primed, 
cytotoxic  T  cells  (Tc) 1 is  an  appropriate  model  for  studying  graft  rejection.  For 
example,  Tc  can  be  found  in  grafts  undergoing  rejection  (1-3),  in  the  spleen  and 
other tissues of primed mice (1, 4, 5), and in sponge matrix grafts (6,  7). In addition, 
extensive in  vitro studies have  demonstrated  the induction and  function  of Tc,  the 
requirement of helper T  cells (Th) for their induction, and the simultaneous induction 
of suppressor T  cells (5, 8-14).  In these studies, it has become abundantly clear that 
the  Lyt-123/23-Tc  2 is different  from  Th  cells (which  are Lyt-1), suppressor T  cells, 
and other T  cells. In spite of the many experiments that support the concept that Tc 
produce graft rejection in vivo, there is little direct evidence demonstrating this, and 
most of the foregoing evidence can be regarded as "indirect." Indeed, it has not been 
clearly demonstrated  that  Tc  have  the only role,  a  major role, or any role in  graft 
rejection in vivo. With this in mind, adult, thymectomized, lethally irradiated, bone 
marrow-restored  (ATXBM)  mice were repopulated with sensitized cells, depleted of 
Lyt-l, Lyt-2, or Lyt-123 subpopulations, and were then examined for the phenotype 
of the T  cell causing skin graft rejection. With antigenic differences arising from the 
11-2 and non-H-2 loci, it was shown that graft rejection was entirely dependent on the 
presence of Lyt-1  cells and,  furthermore,  was  independent  of the presence of Tc.  It 
appears that traditional concepts, linking graft rejection and delayed-type hypersen- 
sitivity (DTH), may well be true, in that both are mediated by Lyt-1 cells. 
Materials  and  Methods 
Mice.  CBA/H  (H-2k), C57BL/6J  (H-2b), and BALB/cBy (1-1-2  a) strains were maintained 
inbred. Male mice were used in all experiments. 
ATXBMPreparation.  Adult thymectomy (16) of CBA/H mice was performed at 5  7 wk of 
age,  followed  2  wk  later  by  lethal  whole  body  irradiation  (800-900  rad)  and  immediate 
intravenous reconstitution with 3 ×  106 Thy-1- syngeneic adult bone marrow cells (depletion 
by 1.0 ml anti-Thy-l.2 serum plus 1.0 ml rabbit complement [RC'] per 2 ×  108 bone marrow 
* Supported by funds obtained from the National Health and Medical Research Council of Australia, 
and grant CA-22080 from the National Institutes of Health, Bethesda, Md. 
1  Abbreviations used in this paper: ATXBM,  adult thymectomized,  lethally irradiated and bone marrow 
restored; CTL-P, precursor cell of the cytotoxic T lymphocyte; DTH, delayed-type  hypersensitivity; MLC, 
one-way mixed lymphocyte culture;  MST, mean survival time;  PFC, plaque-forming  ceils; RC', rabbit 
complement;  SAMG, sheep anti-mouse  immunoglobulin;  SRC, sheep erythrocytes; Tc, cytotoxic T cell 
defined by cell-mediated lymphocytotoxicity; Th, helper T cell; TDTH, T lymphocyte mediating DTH. 
2 We have not been able to demonstrate  directly the presence of an Lyt-l- cell in CBA mice although 
such ceils appear to exist as functional entities and we would agree that the Tc in CBA mice is Lyt-123 
([15]; and this paper). 
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cells, incubated as described below). These mice were used in experiments after an additional 
2-4 wk. 
Antisera.  The production and testing of conventional antisera and monoclonal antibodies 
has been described elsewhere  (13, 17, 18).  3 Antisera with high cytotoxic titers were used in this 
way: (a) anti-Thy-l.2 antiserum was made as (B6.PL(74NS)  ×  RF)FI anti-C57BL/6 (thymus 
titer ~ 1/1,000); (b) Lyt-1.1  monoclonal antibody was made as 129/ReJ anti-B6-Ly-1 '~ (thymus 
cytotoxic titer of supernate ~1/2,000);  and  (c)  Lyt-2.1  monoclonal antibody was  made as 
129/ReJ anti-B6.PL-Lyt-2.1,3.1 (thymus eytotoxie titer of supernate 1/256). 
Sensitization and Preparation of Donor Cells f~r Adoptive Transfer.  CBA/H mice received at least 
two C57BL/6J or BALB/cBy skin allografts and an intraperitoneal dose of 2 ×  107 lymphocytes, 
the last being 2-3 wk before their use as donors for the adoptive transfer of sensitized cells. Cells 
were obtained from the spleen and the mesenteric and axillary lymph nodes of sensitized mice, 
and were teased, depleted of erythrocytes by lysis in warm 0.83% wt/vol ammonium chloride, 
and resuspended as single cell suspensions. For depletion with Ly antibodies, 2-ml aliquots of 
l0  s  cells  were  mixed  with  0.4  ml  anti-Lyt-l.1 antibody (monoclonal), 0.5  ml  anti-Lyt-2.1 
antibody (monoclonal), or 1.0 ml anti-Thy-l.2 antiserum. Cells were then incubated for 30 min 
on ice, and washed and incubated with selected non-toxic RC' at an optimal concentration for 
45 min at 37°C. The viable cells were collected on Ficoll-Isopaque (sp gr 1.09), and the antibody 
and RC' treatments were repeated as before.  Although the doses of antibody were in excess for 
maximum cytotoxicity, the second treatment was required for successful adoptive transfer and 
presumably removed residual antigen-bearing  cells that survived the first  treatment. Testing 
depleted cell populations  by cytotoxicity demonstrated >98% depletion and this was exemplified 
by assays of cells taken after transfer (see Results). Anti-Thy-1.2  or anti-Lyt-1.1 treatment killed 
50% of the spleen plus lymph node cell suspension, whereas anti-Lyt-2.1 treatment killed 25% 
of the cells. Aliquots of cells were adoptively transferred, intravenously, in volumes of 0.15 or 
0.20 ml into recipient ATXBM-CBA mice. 
Rosette Depletion.  Sheep erythrocytes (SRC) coupled with sheep anti-mouse gammaglobulin 
(SAMG) and chromic chloride were used to form rosettes with Ig  ÷ cells (19). Nonrosetting cells 
were collected from the interface of Ficoll-Isopaque solution after centrifuging for  12 rain at 
1,000 g, and Ig  ÷ cells were recovered from the pellet. Less than 2% of interface cells were capable 
of forming Ig rosettes  and >90% were sensitive to lysis by anti-Thy-l.2 antiserum plus RC'; 
pellets contained 90-95%  rosetting lymphocytes.  Hence  the  interface consisted of T  cells, 
whereas B cells were isolated in the pellet. Rosettes formed with protein A-coupled SRC (20) 
were also used with monoclonal antibodies to detect spleen T  cell subsets. 
Skin Grafts.  Skin for grafting was obtained from the dorsal or ventral surface of the donor 
mouse and grafts 0.5-1.0 cm  2 were applied to the thoracic wall (21). Graft rejection was read 
as total graft necrosis and expressed  as the mean survival time (MST). 
Plaque-forming Cell (PFC) Assay for  Th Function.  A splenic PFC to SRC was performed 5 d 
after intravenous injection of 0.2  ml of 2% vol/vol SRC  (22). Both direct and indirect PFC 
(detected  with  rabbit anti-mouse Ig)  were  assayed,  using guinea pig serum  as  a  source of 
complement. 
Cytotoxic  T  Lymphocyte Precursor Cell  (CTL-P)  Frequency Determinations.  The  frequency of 
CTL-P in lymphoid cell suspensions was determined as previously described (23). For each cell 
suspension in which CTL-P frequencies were determined, a minimum of 32 replicates for each 
of at  least  four responder cell  doses  were cultured in U-bottomed microtiter trays  (Linbro 
Chemical Co.,  Flow  Laboratories,  Inc.,  Hamden, Conn.) with  3  ×  105  C57BL/6-nu/nu  or 
BALB/c-nu/nu spleen stimulator cells in modified Eagle's medium supplemented with 10% fetal 
calf serum.  7 d  later, each microculture was  assayed for cytotoxicity by replacing 100/~1 of 
culture medium with  100 pl target cell suspension containing 104 ~lCr-labeled EL4 or P815 
tumor target cells. Wells were regarded as containing cytotoxic activity if they yielded specific 
51Cr release  3  SD  above the  mean  isotope  release  from  104  cells  cultured alone. A  linear 
relationship existed between the dose of responder cells on a linear scale and the frequency of 
negative wells on a logarithmic scale. CTL-P frequencies were determined as the inverse of the 
responder cell dose required to generate 37% negative wells (24). 
3 Hogarth, P. M., J. Edwards, I. F. C. McKenzie, and F. Y. Liew. Monoclonal antibodies to the Lyt-2.1 
murine cell surface antigens. Manuscript submitted for publication. 1046  Lyt-1 CELLS AND SKIN GRAFT REJECTION 
Conditioned Medium.  CBA  spleen cell  suspensions were  incubated for  2  h  with  5 #g/ml 
concanavalin A,  washed,  and  incubated overnight before  collecting the  supernatant fluid 
(conditioned medium), which was used as a source of helper activity. 
DTH.  A DTH response to allgeneic lymphocytes was elicited by sensitization with 3 ×  10  v 
spleen cells injected subcutaneously and followed  6 d later by footpad challenge with 5 ×  106 
lymphocytes in a volume of 0.05 ml. The 24-h footpad swelling was measured using Poco-Test 
calipers  (Schnelhaster, Diatest  U.  K.  Ltd.,  London, England) to  +0.05  mm.  Results were 
expressed  as the percent specific increase in footpad thickness. 
Statistical Analysis.  Data were calculated to give mean and standard errors,  and statistical 
significance was determined by Student's t test. 
Results 
Dose  Response  Studies for  Adoptive  Cell  Transfer and  T  Cell  Dependence of Allografl 
Rejection.  The protocol used to prepare ATXBM-CBA mice is outlined in Fig.  1. In 
periods of observation of 50-200 days ATXBM-CBA mice were incapable of rejecting 
skin allografts, as were animals repopulated with Thy-1.2-depleted sensitized lympho- 
cytes (Table I). In contrast, mice receiving untreated sensitized cells rejected grafts in 
10-14 d. It was found that  1 ×  106 viable sensitized lymphocytes (spleen plus lymph 
node) restored the immune response in ATXBM-CBA mice to the maximum rate of 
allograft  rejection where  mean  survival times  in  six  different  experiments  varied 
~ 
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Fro.  1.  Scheme  of preparation and use of ATXBM-CBA/H mice. Adult thymectomized mice 
were lethally irradiated (800 rad) and reconstituted with 3 X 106 bone marrow cells depleted of 
Thy-l.2 cells (antiserum plus RC') within 24 h of irradiation. After 3-4 wk, ATXBM mice were 
given variously treated spleen cells plus lymph node cells and a full thickness skin graft and were 
then observed for a specific response against the skin graft. LOVELAND,  HOGARTH,  CEREDIG,  AND  McKENZIE 
TABLE  I 
T Cell Dependence o/the Adoptively Transferred Allografl Response 
1047 
Number of 
Experiment  Cells transferred*  recipients  Graft survival:~ 
1  None  4  >50 
7 X  106 untreated  5  14.2:1:1.0 
8 x  106 Ig depleted  6  13.7 +  0.7 
7 X  106 Thy-l.2 depleted  5  >44 
2  None  5  > 150 
10 X  106 untreated  8  10.1 -t- 0.7 
8 X  106 Thy-l.2 depleted  6  >130 
3  1.5 x  l0  s untreated  8  11.l  zlz  1.4 
1 X  106 Thy-l.2 depleted  4  >60 
* Viable spleen plus lymph node cells from sensitized donors; Ig depleted by separa- 
tion of SAMG-rosettes on Ficoll-Isopaque gradients or depleted with anti-Thy-l.2 
antiserum plus RC'. 
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FtG.  2.  Dose response of the adoptive transfer of sensitized lymphocytes into ATXBM-CBA mice 
and subsequent skin graft rejection. Groups of 5-10 mice received viable spleen cells plus lymph 
node cells 1 d before a C57BL/6 skin graft. Results are expressed as the MST :1: SE. 
between 9.7 and 14.2 d. The transfer of<106 viable lymphocytes resulted in a delayed 
rejection  (>15  d)  (Fig.  2), whereas up  to  107  viable cells did  not  greatly affect the 
survival time over that  produced  with  106  cells.  In  most experiments,  ~I-3  X  106 
viable cells were adoptively transferred. 1048  Lyt-1 CELLS  AND SKIN GRAFT REJECTION 
TABLE II 
Adoptive Transfer of Lyt-l-depleted Sensitized Cells to A TXBM-CBA Mice 
Lyt-I  Number of  Graft survival:[:  Experiment  Adoptive cell dose*  depleted  recipients 
1  33  ×  105  --  7  12.7  ±  1.5 
65 X 105§  +  9  34.9 + 4.1  / 
2  ,4,  10 X 105  +  7  >62  / 
8 ×  105  +  4  >210 
3  } 40 ×  105  --  4  27.5 ± 4.9 
)  13 ×  105  +  4  >68 
4  ~  50 ×  105§  --  4  12.5 ± 0.5 
!  ) 33 ×  105  -  5  18.2 ±  1.6 
)  31 X 105  +  3  >100 
* Viable cell  dose of spleen  plus  lymph node  cells, either treated  (+)  with  anti-Lyt-l.l 
antibody plus RC', or not (-). 
:~ Mean + SE or duration of observation. 
§ Second adoptive transfer of spleen plus lymph node cells 3 5 mo after the first skin graft 
(see text). 
To exclude any role of B  (Ig  +)  cells in allograft rejection, Ig  + cells were  removed 
from a  sensitized spleen plus lymph node cell suspension.  Mice given untreated cells 
rejected their grafts in 14.2 d, whereas those given B-depleted cells (Ig-) rejected grafts 
in 13.7 d, i.e., Ig  ÷ B cells were not essential for, and did not mediate the rapid rejection 
response to allografts (Table  1). 
Lyt-1 Dependence of the Allograft Response.  Depletion of the primed cell inoculum of 
cells  bearing  the  Lyt-1  specificity prevented  graft  rejection.  Four  groups  of mice 
receiving Lyt-1--sensitized T  cells were  observed  for  at  least  60  d,  and  some  were 
observed until death at 210 d. In all groups, rejection was delayed: from  12.7 to 34.9 
d  (experiment  1, Table II) and from 62 to 200 d  in the other experiments, i.e., in the 
latter experiments the grafts did not reject in mice lacking Lyt-1 cells (Table II). One 
group  of mice that  had  rejected  grafts  in  34.9  +  4.1  d  (experiment  1)  was  used  as 
donors for a  second adoptive transfer assay. In Table II (experiment 3), it can be seen 
that alloreactivity was transferable from these mice (MST 27.5 +  4.9 d), but that the 
rejection response was sensitive to anti-Lyt-1.1 antibody treatment because the grafts 
on treated mice did not reject during an observation period of >68 d. Presumably the 
shortened survival (35 d) in the first transfer was due to residual Lyt-1 cells that were 
eradicated in  the second  transfer.  If the cells were  taken  from  ATXBM-CBA  mice 
repleted with untreated cells (experiment 4;  MST  12.5  +  0.5 d), a  similar result was 
observed: untreated cells transferred alloreactivity (MST  18.2 +  1.6 d), whereas Lyt- 
1-depleted cells were unable to transfer alloreactivity (no rejection at  100 d). 
Lyt-2 Depletions and the Allograft  Response.  Cell depletion by monoclonal anti-Lyt- 
2.1  antibody  plus  RC'  did  not  significantly delay the  graft  rejection  mediated  by 
sensitized cells (Table III). In three experiments, mice that received 106 or more Lyt- 
2.1-depleted sensitized lymphocytes (i.e., Lyt-l+2  -  cells) rejected skin grafts in mean 
times ranging from  11.0  to  13.5  d. These results were similar to those found in mice 
that received untreated cells and rejected grafts in mean times of 11.6-12.7 d. Mixing 
Lyt-l-depleted  cells  with  either  Lyt-2-depleted  cells  or  with  a  limiting  dose  of 
untreated cells was  found  to have no effect on  graft rejection as mediated by either 
Lyt-2-depleted or untreated  inocula  (Table III, experiment  3).  Injection of 2  ×  106 LOVELAND,  HOGARTH, CEREDIG, AND McKENZIE  1049 
TABLE  III 
Repletion of A TXBM-CBA Mice with Depleted Lymphocytes  from C57BL/ 6-immunized CBA Donors 
Adoptive cell dose*  Number of 
Experiment  recipients  Graft survival:~ 
Untreated  Lyt-  1 depleted  Lyt-2 depleted 
10X 105  --  --  7  11.6+0.7 
--  --  25  ×  105  15  13.5 ±  0.4 
10 X 105  --  --  6  12.7 ± 0.8 
6 X 105  --  --  5  15.8 ± 0.7 
--  --  30  X  105  5  11.0  ±  0.3 
--  --  10  X  10  s  8  12.0  ±  0.4 
--  --  5  ×  105  7  15.4  ±  2.0 
--  --  --  5  >60 
20 ×  105  --  --  5  12.4 ± 0.7 
--  --  20  ×  105  6  13.0  +  1.5 
--  20  x  105  --  6  >40 
--  20  x  105  20  x  105  7  15.0  ±  1.1 
--  10  ×  l0 s  10  x  105  7  13.4  ±  0.6 
2 ×  105  --  --  6  17.8 + 0.8 
2 ×  105  20 X 105  --  6  16.4 + 0.5 
--  --  --  4  >80 
* Viable spleen plus lymph node cells, either not treated or depleted as described in the text by anti-Lyt- 
1.1 monoclonal antibody or anti-Lyt-2.1 monoclonal antibody plus RC'. 
:~ Mean ± SE or duration of observation. 
Lyt-2-depleted cells resulted in mean  graft survival of 13.0  :l:  1.5  d, which was not 
affected by the addition of Lyt-l-depleted cells (MST  15.0 :t:  1.1  d, P  <  0.15). More 
important,  a  limiting dose of untreated  cells (2  ×  105; MST  17.8  _  0.8  d)  was  not 
significantly affected when mixed with 2  ×  106 Lyt-l-depleted cells (MST  16.4 +- 0.5 
d, P  <  0.10). Hence the allograft response in sensitized mice appeared to be mediated 
by Lyt-l+2  -  cells with  no  apparent  synergistic effect  of Lyt-l-2  +  cells or  Lyt-l+2  + 
cells. 
Lymphocyte Populations in  the  Spleens of Reconstituted A TXBM-CBA  Mice.  The  cell 
surface phenotype was determined in the spleens of reconstituted mice to determine 
the  efficacy  of  the  depletion  protocol.  Protein  A  rosetting  assays,  in  which  the 
background  was  <10%,  were  used  to  determine  the  relative  frequencies  of Lyt-1, 
Lyt-2,  and  Thy-1  antigen-bearing  cells  50-200  d  after  adoptive  transfer.  It  was 
observed  that  ATXBM-CBA  mice  that  had  received  sufficient  cells  (>1  ×  106 
sensitized lymphocytes) for graft rejection in minimum  time  (10-12  d)  had  normal 
total counts of splenic lymphocytes (7-10 ×  107 cells; data not shown), but often had 
lower percentages of T  cell subsets  than  normal  mice  (Fig.  3).  For instance, results 
showed  18-21% Thy-1  and  Lyt-1 cells compared with  30-35%  in normal mice;  and 
13% Lyt-2 cells compared with 20% in normal mice. However, specific subset depletion 
was apparent  in the spleens of mice that either had not been repleted (ATXBM)  or 
had received anti-Thy-l.2-treated inocula (3% Thy, 2% Lyt-1, 2% Lyt-2), anti-Lyt-1- 
treated inocula (2% Lyt- 1-, or anti-Lyt-2-treated inocula (2% Lyt-2) (Fig. 3). The anti- 
Lyt-l.1  monoclonal  antibody reacted with slightly more cells than  the anti-Thy-l.2 
antiserum, presumably due to a  higher affinity of binding. It was therefore concluded 
that  antibody  depletions were  satisfactory both  in  vitro  and  for  up  to  200  d  after 
adoptive transfer into ATXBM  mice. 1050  Lyt-I  CELLS  AND  SKIN  GRAFT  REJECTION 
FIG.  3.  Percentage of spleen T  cell antigens in repleted ATXBM-CBA mice. All mice received a 
skin graft 1 d after the adoptive transfer of spleen cells plus lymph node cells and were killed 50-200 
d  later.  No  differences were  found with  time elapsed, so the data were pooled.  Percent specific 
Protein A rosettes corrected for background reaction of 3-5%; [], Thy-1.2 cells; ll, Lyt-1.1 cells; and 
k~, Lyt-2.1 cells. 
TABLE  IV 
Helper Activity in Repleted A TXBM-CBA Mice as Indicated by a PFC Response 
PFC/106 IgM  Spleen cells IgM + 
Experiment  Spleen donor*  (direct)  IgG (indirect):~ 
1  A.  Repleted  16 ±  3  31  ±  8 
B.  Lyt-1 depleted  <2  <3 
C.  Lyt-2 depleted  49 ±  13  168 +  28 
D.  B+C  49+  10  72±  16 
2  E.  Repleted  44 ±  6  42 ±  8 
F.  Lyt-1 depleted  10 -t- 1  14 +  2 
G.  Lyt-2 depleted  35 "4- 7  50 +  12 
H.  F+G  26±8  33±3 
I.  Normal  mouse  con-  267 ±  14  730 ±  48 
trol 
3  J.  Repleted  111  ±  7  162 ±  22 
K.  Lyt-I depleted  10 ±  2  3 ±  1 
* ATXBM-CBA  mice  repleted  with  sensitized  spleen  plus  lymph  node  cells  as 
described in the text (50-100 d earlier) and killed 5 d  after injection of SRC. 
:~ Mean PFC zlz SE for three donors in each assay. 
Helper Cell Activity ,n Reconstituted Mice.  As an  additional  measure  of the  depletions 
and  to examine  the  nature  of the  residual  cell populations  in  reconstituted  mice,  the 
helper  T  cell  activity  for  the  antibody  response  to  SRC  was  assayed  50-100  d  after LOVELAND,  HOGARTH,  CEREDIG, AND McKENZIE 
TABLE  V 
Limiting Dilution Analysis of Cytotoxic Spleen Cells 
1051 
Target  CTL-P fre-  Percent de- 
Experiment  Treatment of spleen cells*  cell  quency~  pletion 
Normal CBA responder 
1  None  P815  1/4,300  -- 
A.  Anti-Lyt- 1.1  P815  <1/96,000  95.5 
2  None  P815  1/31,500  -- 
B.  Anti-Lyt-2.1  P815  <1/315,1)00  >90 
A +  B  P815  <1/285,000  >89 
Sensitized  CBA responder 
3  None  EL4  1/1,000  -- 
A.  Anti-Lyt-1.1  EL4  <l/120,000  >99 
4  None  P815  1/2,200  -- 
A.  Anti-Lyt-  1.1  P815  < 1/3,000,000  >99.9 
C.  Anti-Lyt-l.1 plus conditioned medium  P815  <1/3,000,000  >99.9 
D.  Conditioned medium only  P815  1/1,900  -- 
5  None  P815  1/5,800  -- 
B.  Anti-Lyt-2.1  P815  < 1/85,000  >93 
A +  B  P815  <1/122,000  >95 
* Responder spleen cells alone; A, treated with anti-Lyt-l.l antibody and RC'; B, treated with anti-Lyt- 
2.1 antibody and RC'; C and D, adding conditioned medium. 
~: Limiting dilution analysis of cytotoxic precursors  or the limit of detection of the culture system. 
TABLE  VI 
Correlation of DTH Responses and Skin Graft Rejection 
Skin graft re-  Number of  Percent swelling~  DTH re- 
Status of responder  jection*  recipients  sponse 
ATXBM  No  4  3.2 +  1.9  -- 
Yes  6  17.6 :t: 6.5  + 
Lyt-1 depleted  No  13  3.6 +  1.1  - 
Yes  4  20.1:1:4.7  + 
Lyt-2 depleted  No  0  -- 
Yes  32  35.7 :l: 3.7  + 
Thy-l.2 depleted  No  3  6.4 +  4.6  - 
Yes  0  -- 
Reconstituted  No  0  -- 
(no depletion)  Yes  10  42.3 :tz 5.9  + 
* C57BL/6 skin graft 40-100 d after adoptive transfer of spleen plus lymph node ceils. 
Percent increase  in footpad thickness corrected for nonspecific swelling of the other footpad. Mean :1: SE. 
reconstitution and grafting. Lyt-1-depleted animals had barely detectable numbers of 
direct  (IgM)  PFC  (<10/106  spleen  cells),  in  comparison  with  mice  that  received 
untreated cells, Lyt-2-depleted cells, or a  mixture of Lyt-1-depleted and Lyt-2-depleted 
lymphocytes  (16-49  PFC/106  spleen cells)  (Table  IV).  Fully repleted  ATXBM  mice 
(i.e.,  graft  rejection within  10-15  d)  had  only  16-55  direct  PFC  per  106  spleen cells, 
compared  with  267  _  14  per  106  spleen  cells  in  normal  animals.  In  addition,  mice 
that  received untreated,  Lyt-2-depleted,  or the mixture of Lyt-l-depleted  and  Lyt-2- 
depleted  cells,  all  had  significantly  more  indirect  (IgM  plus  IgG)  PFC  than  those 
given Lyt-l-depleted  cells. It was evident that  Lyt-1-depleted mice lacked effective T 
helper function, whereas Lyt-2-depleted mice had normal or increased helper function, 
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In  Vitro Determination of CTL-P Frequencies.  Spleen cells from normal and reconsti- 
tuted mice were used as responder cells in mixed lymphocyte cultures (MLC), which 
were assayed for cytotoxicity 7 d  later. Using this culture method, the frequency of 
anti-H-2  a CTL-P in unprimed spleen cell suspensions was  1/5,000 and after specific 
sensitization  this increased to  1/1,500  (Table V).  Using responder cells depleted of 
Lyt- 1 cells, the frequency of CTL-P was reduced by >95% and in two experiments by 
99%.  Although linear semilogarithmic plots of responder cell dose vs. proportion of 
negative cultures were consistently obtained, it was conceivable that the development 
of cytotoxicity was  dependent  upon  the  presence  of helper  cells  provided  by  the 
responder cells, and  that  Lyt-1 depletion simply removed these accessory or helper 
cells.  Therefore, the MLC was set  up with  Lyt-l-depleted responder cells plus H-2 
allogeneic nude spleen stimulator cells that were cultured in modified Eagle's medium 
supplemented with 10% conditioned medium obtained from concanavalin A-activated 
spleen cell suspensions. (This medium was known to contain helper activity necessary 
for the generation of CTL-P from limiting numbers of responder cells. Rh. Ceredig, 
unpublished  observations.)  Addition  of conditioned medium  had  no effect on  the 
responses of either Lyt-1-depleted or untreated cell suspensions (T~ible V), indicating 
that depletion of Lyt-1 cells did not merely remove T  cell help, but in fact removed 
a Tc bearing the Lyt-1 specificity. Treatment of responder cells with the monoclonal 
anti-Lyt-2.1  antibody  also  reduced  the  CTL-P  frequency  by  89%,  whether  the 
responder cells were sensitized or not  (Table V).  Hence both  Lyt-1 treatment  and 
Lyt-2 treatment inhibited the generation of cytotoxicity, which indicates that the Tc 
was  Lyt-123.  However,  this  result  could  also  be  due  to  a  synergistic  interaction 
between Lyt- 1 and Lyt-2 cells. Nevertheless, mixing Lyt- 1- and Lyt-2- cell suspensions 
did not result in the generation of cytotoxicity in the MLC, because there was 89 and 
95% depletion of CTL-P in two such experiments. Therefore, the CTL-P generated in 
MLC was Lyt-123 and the monoclonal antibodies could clearly deplete this popula- 
tion. 
DTH Responses Correlate with Graft Rejection.  All groups of reconstituted mice were 
tested for the ability to elicit a DTH response generated ~50 d after adoptive transfer. 
Mice  that  were  unable  to  reject  a  skin  graft  had  no  significant  footpad swelling, 
whereas those which had rejected a skin graft, even in a delayed manner, were found 
to exhibit specific swelling of 18-44% (Table VI). This swelling was maximal at 24 h 
and  rapidly  reduced  thereafter  (data  not  shown).  The  ability  to  elicit  the  DTH 
response required an Lyt-1 cell, because ATXBM mice reconstituted with either Lyt- 
1-depleted or Thy-1-depleted cells, or no cells at all did not exhibit footpad swelling. 
In contrast, Lyt-2 depletion was without effect on the expression of either the DTH 
response  or  on  allograft  rejection.  In  all  72  mice  examined,  there  was  complete 
correlation between skin graft rejection and the DTH response (Table VI). 
Discussion 
There is evidence that Tc are generated during graft rejection in vivo (see  Intro- 
duction),  and  it  is  established  that  Ly cell  surface  phenotypes distinguish  the  Tc 
subset  from  other T  cell  subsets.  Strong  evidence suggests  that  Tc are  the  prime 
mediators of rejection. However, our data show that this is not the case and that skin 
graft rejection in the mouse is mediated by Lyt- i cells that do not have killer function 
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that  graft  rejection  and  DTH  responses  are  similar,  if not  identical,  phenomena. 
These findings throw considerable doubt on the validity of using in vitro studies of Tc 
as the most appropriate model to examine graft rejection. Because of the implications 
of these studies our model  needs to be discussed  in  detail  and  compared to other 
relevant studies. As indicated, the evidence of a role of Tc in graft rejection has been 
extensively reviewed elsewhere (5,  12,  13) and will not be reviewed here. However, it 
should  be emphasized that  most  of the  evidence accumulated  is  indirect, showing 
that  Tc  are  generated  during  graft  rejection,  can  be  recovered during  and  after 
rejection, and are not induced in vivo apart  from the ability to reject grafts. These 
findings do not prove that Tc do mediate graft rejection. 
The model that we used appeared to be suitable for the study of the separate and 
joint roles of Lyt-1, Lyt-2, and Lyt-123 cells in graft rejection. As expected, the T  cell- 
deficient ATXBM mice were unable to reject grafts. Direct typing of spleen (Table 
IV)  and  lymph  nodes  and  examination  for  thymic  remnants  confirmed  T  cell 
deficiency (although several "ATXBM" mice did eventually reject their grafts and 
were found to have small numbers of T  cells and residual thymic tissue;  these were 
excluded from the study). The careful dose response studies  (Fig. 2)  in repopulated 
mice demonstrated a  limiting cell effect of sensitized ceils to mediate graft rejection 
and Thy-1 depletion showed the T  cell dependence (Thy-1  + Ig- cell; Table I). Thus 
the  model  appeared  to  conform  to  the  usual  criteria  applied  to  T  cell-mediated 
reactions. However, the most crucial questions concern the cell depletions. Were the 
depletions adequate? Would the results be explained by a  more thorough depletion 
with the Lyt-l.1 rather than the Lyt-2.1 antibodies? do the monoclonal antibodies 
really bind the defined Lyt-1 and Lyt-2 determinants? These antibodies do recognize 
the defined determinants based on their strain and tissue distributions, their reaction 
with Lyt-1 and Lyt-2 congenic strains, and a  67,000-mol wt molecule is precipitated 
by the  anti-Lyt-l.1  antibody  (17). a Furthermore, both reagents  have been demon- 
strated to react with Tc (Table V;  17,  18), which, in CBA mice, is an Lyt-123 cell 
(15). In addition, the T  helper cell was identified in these studies, as expected, as an 
Lyt-l+2  -  cell (Table IV). Thus, by the usual genetic and functional criteria, the two 
monoclonal antibodies appear to react with the Lyt-1 and Lyt-2 determinants.  We 
also consider that the depletions were satisfactory. After exposing the cells twice to 
excess amounts of the monoclonal antibodies and to complement, we were unable to 
detect the appropriate cell and, at  various times after adoptive transfer, these cells 
were  not  detected  in  mice  in  significant  numbers  by  rosetting  methods  (Fig.  3). 
Finally, by repeating the depletion on Lyt- 1.1-depleted mice (following a long-delayed 
skin  graft  rejection),  the  key  role  of the  Lyt-1  cell  in  graft  rejection  was  again 
demonstrated  (Table II). In addition, the in vitro treatments were successful in the 
depletion of Tc with both antibodies (Table V) and with anti-Lyt-1.1 for the helper 
T  cell. Although it may be considered that depletions are never 100% successful and 
that  small  numbers of cells could be transferred, and  could multiply and  produce 
effects, we were given no reason  to interpret data in  this way and were unable to 
detect such a clonal expansion of Lyt- 1 or Lyt-2 cells in mice receiving cells depleted 
of these populations  (Fig.  3).  It could be suggested that  the studies are deficient in 
that a "negative selection" has been used, and studies are in progress to transfer pure 
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removal of Lyt- 1 cells is in fact a positive selection for Lyt-2 cells, and vice versa with 
Lyt-2 depletion (Table VII). 
On  the basis of the foregoing points, the results can be summarized here and  in 
Table VII as:  (a)  depletion of cells bearing the Lyt-1 antigen  (Lyt-1  and  Lyt-123) 
removed Tc, Th, and graft rejection capability; (b) depletion of cells bearing the Lyt- 
2 antigen  (Lyt-2 and Lyt-123) removed Tc only, with Th and graft rejection ability 
remaining;  (c) mixing of cells obtained in (a) and  (b) demonstrated Tc to be absent, 
whereas Th and graft rejection were retained. 
That the cell that mediates graft rejection has no killer function was clearly shown 
when Lyt-2 depletion removed the CTL-P but did not prevent skin graft rejection. 
Further, when in vitro helper activity for the generation of cytotoxicity was provided 
"in excess" by the addition of conditioned medium or by the mixing of Lyt-1-depleted 
and Lyt-2-depleted populations, cytotoxicity remained at background levels. Hence. 
the results show: graft rejection for T  cell, Lyt-1; for Th, Lyt-1; for To, Lyt-123; i.e., 
there is a clear distinction between cells producing graft rejection and the Tc, and in 
addition, our studies using sensitized cells have not demonstrated any synergy in graft 
rejection between the three T  cell subsets examined. 
How do Lyt-1 cells produce graft rejection, and is there a relationship between this 
cell and other Lyt-1 cells (i.e.,  T  lymphocytes mediating DTH  (TDTH) and Th)? At 
present we cannot distinguish these three possible Lyt-1 cell types. It seems that Th 
and TDTn are different cells, e.g., help and DTH are different phenomena. However, 
there are compelling reasons to consider that  TDTn and T  (graft rejection) are the 
same cell, and that DTH and skin graft rejection are different manifestations of the 
same response (Table VI). Traditionally, and before the discovery of T  cell subsets, 
these phenomena were linked  (25). However, in recent studies of DTH to the H-Y 
antigen,  there is  a  close correlation between the DTH reaction and  graft rejection 
(26).  Furthermore, it should be noted that in the H-Y model, graft rejection and the 
detection  of Tc  are  independent  phenomena.  These  findings,  taken  together with 
ours, indicated that graft rejection and the detection of Tc are mediated by different 
cells in what may be a general dissociation of the two phenomena. Conversely, there 
appears to be a close association between graft rejection and the DTH phenomena for 
H-2 differences (Table VI), H-Y differences (26), and for other antigenic differences 
(I.  F.  C.  McKenzie, unpublished  observations). The linking  of graft  rejection and 
DTH should have important implications for mechanistic and therapeutic models to 
study graft rejection in man and we note that one of the best predictive tests for graft 
survival  in  man  is  the  DTH  status  of the  recipient awaiting  transplantation  (27). 
Therefore,  the  studies  reported  here  are  important  in  both  the  analysis  of  the 
mechanism and the treatment of graft rejection, for if they are applicable to all types 
TABLE  VII 
Summary of Findings of Functional T Cell Populations 
Graft re-  Antibody  Cells removed  Cells present  Tc  Th  jecfion  DTH 
A.  None  None  Lyt-l, Lyt-123,  Lyt-23  +  +  +  + 
B. Anti-Lyt-l.1  Lyt-1,  Lyt-123  Lyt-23  .... 
C. Anti-Lyt-2.1  Lyt-123,  Lyt-23  Lyt-1  -  +  +  + 
D.  B + C  Lyt-123  Lyt-1, Lyt-23  -  +  +  + LOVELAND, HOGARTH, CEREDIG, AND McKENZIE  1055 
of gratis  (see below), then we should be considering ways to neutralize lymphokines 
and other secondary mediators involved in DTH responses (28), rather than consid- 
ering the removal of the Tc. 
What then is the role of the Tc if not for graft rejection? It is clearly the mediator 
of a sophisticated, potent system of specific in vitro cell lysis. At present, we are unable 
to answer this question but would suggest that cell lysis on a single cell contact basis 
may not  be an efficient mechanism  for the removal of a  whole graft, where tissue 
repair mechanisms may maintain the status quo and the amplification mechanisms 
available via lymphokines, as in the DTH phenomenon, may be a better explanation 
of the rapid graft rejection. It may be that Tc are primarily involved in the lysis of 
virus-infected target  cells and  may also  be the  true  mediators of several  forms of 
autoimmune disease rather than of graft rejection. However, we should conclude on 
a  note of reservation.  Our  studies  have examined the  response  to  the whole H-2 
complex (plus non-H-2 differences) and have exclusively examined skin graft rejection. 
Preliminary data suggests that our results will also apply to lymphoid tumor grafts; 
however, they may not be applicable to vascularized grafts or to individuals receiving 
immunosuppressive agents.  Current  examination of these variables should have an 
important bearing on the understanding of the mechanisms and treatment in man of 
graft rejection. 
Summary 
The Ly phenotype of cells mediating skin  graft  rejection was  determined  using 
monoclonal  anti-Lyt-l.1  and  Lyt-2.1  antibodies  in  CBA  mice  that  received CBA 
lymphoid cells from mice sensitized to C57BL/6; i.e., alloantigenie differences arising 
from the H-2 and non-H-2 loci. It was clear that graft rejection was due wholly to the 
presence of Lyt-1 cells in the inoculum and that Lyt-123 or Lyt-23 cells had no effect. 
Furthermore, no synergism was noted between Lyt-1 and Lyt-2 cells.  In this model, 
both the cytotoxic T  cell and cytotoxic lymphocyte precursors were shown to be Lyt- 
123 and these could be depleted from sensitized Lyt-1 populations that mediated graft 
rejection. Thus cytotoxic T cells are not responsible for skin graft rejection, but rather, 
this is mediated by an Lyt-1 cell. Whether this T  cell is distinct from other Lyt-1 cells 
(T helper, T cells mediating delayed hypersensitivity) is not clear at present, but other 
evidence, and traditional concepts, link graft rejection and delayed type hypersensi- 
tivity as being different manifestations of the same mechanism. 
Received  for publication 4 December 1980. 
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